Effects of Gimeracil and Oteracil Porassium Capsules Combined with Oxaliplatin in the Treatment of Advanced Gastric Cancer in the Elderly Patients and Their Effect on Serum Level of ESM-1 and IGFBP3

OBJECTIVE To explore the effects of Gimeracil and Oteracil Porassium Capsules combined with oxaliplatin in the treatment of advanced gastric cancer in the elderly and their effects on serum levels of endothelial cell specific molecule-1(ESM-1) and insulin-like growth factor binding protein-3 (IGFBP3). METHODS From April 2016 to October 2017, 124 elderly patients with advanced gastric cancer who were treated in Henan Provincial People's Hospital were selected as observation objects, and they were divided into control group and observation group according to the random number table method, with 62 cases each group. Patients in the control group were treated with capecitabine and oxaliplatin, while patients in the observation group were treated with Gimeracil and Oteracil Porassium Capsules and oxaliplatin. The clinical efficacy, adverse reactions survival rate, tumor marker level and serum ESM-1 and IGFBP3 levels of the two groups were observed and compared. RESULTS After all treatment courses, the remission rate of the observation group was 41.94%, which was significantly higher than that of the control group (25.81%). MMP-2, MMP-9, CA125 and CEA of the observation group and the control group were significantly lower than those before treatment (P<0.05), and the index level of the observation group was lower than that of the control group (P<0.05). Compared with before treatment, the serum ESM-1 level of 2 groups after treatment was significantly reduced (P<0.05), while IGFBP3 level was significantly increased (P<0.05), and the observation group was more obvious than the control group. As for adverse reactions, the incidence of vomiting and diarrhea in the observation group was significantly lower than that in the control group (P<0.05). The 24-month survival rates of the observation group was 51.60%, which was significantly higher than that of control group (33.87%). CONCLUSION Gimeracil and Oteracil Porassium Capsules combined with oxaliplatin has a good therapeutic effect on elderly patients with advanced gastric cancer, which can reduce the serum ESM-1 level, increase the serum IGFBP3 level, and improve the survival of patients with low adverse reactions. The therapy is safe and reliable, and worth promoting.